151 results on '"Trabacchi Elena"'
Search Results
2. Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
3. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
4. P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION
5. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy
6. Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis
7. Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study
8. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
9. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era
10. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients
11. CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients
12. Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial
13. Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors
14. Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way
15. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib
16. A Singular Case of Multiple Myeloma and Primary Biliary Cirrhosis Strictly Associated in Pathogenesis and Response to Alkylating Therapy
17. Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia
18. Regression of Low-Grade Non-Hodgkinʼs Lymphoma After Treatment With Pegylated Interferon Plus Ribavirin in Hepatitis C Virus Infection
19. ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia
20. Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin’s Lymphoma: A Multicenter Italian Experience
21. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
22. Reply to Pfirrmann and Hasford
23. Testing Sokal[apos]s and the new prognostic score for chronic myeloid leukaemia treated with [agr]-interferon
24. Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature
25. Corrigendum to “Ibrutinib as a bridge to transplant in high-risk chronic lymphocytic leukemia: A case report and review of the literature” [Leukemia Res. Rep. 8 (2017) 21–23]
26. Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted
27. Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis
28. Efficacy and Safety of Bosutinib in Chronic Phase CML Patients Developing Pleural Effusion Under Dasatinib Therapy
29. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders
30. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib
31. Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis
32. A Population-Based Study of Chronic Myeloid Leukemia Treated with Imatinib in First Line
33. Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party
34. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line
35. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens
36. Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial
37. Arterial Thrombotic Events in CML Patients Treated with First-Line Nilotinib: Incidence, Management and Impact on the Long Term Outcome — a Gimema CML WP Analysis
38. SETD2 Loss of Function Is a Recurrent Event in Advanced-Phase Chronic Myeloid Leukemia
39. Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party
40. Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
41. Inversion time prolongation at late enhancement cardiac magnetic resonance in a myeloma patient
42. Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509
43. Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party
44. Presentation of Esophageal Cancer With Solitary Splenic Metastasis
45. The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Related Non-Hodgkin Lymphoma: An Update of a Multicenter Study.
46. Imatinib-Related Neutropenia in Chronic-Phase Chronic Myelogenous Leukaemia: Safety and Efficacy of Granulocyte-Colony-Stimulating Factor (Filgrastim) Use.
47. In Reply
48. Primary Lung Lymphoma
49. Prediction of Response to Imatinib by Prospective Quantitation of BCR-ABL Transcript in Late Chronic Phase Chronic Myeloid Leukemia PatientsBy GIMEMA Working Party on CML.
50. ABL Mutations in Late-Chronic Phase Chronic Myeloid Leukemia Patients with Cytogenetic Refractoriness to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival. on behalf of the GIMEMA Working Party on Chronic Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.